Results 61 to 70 of about 37,609 (234)

Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases.

open access: yes, 1994
A number of unsubstituted aromatic hydrocarbons, azaheterocycles, oxaheterocycles and cyclic ketones were screened for their inhibitory potency towards monoamine oxidases (MAO; EC 1.4.3.4.) A and B.
Thull U, Testa B
core   +1 more source

Computationally Assisted Lead Optimization of Novel Potent and Selective MAO-B Inhibitors

open access: yesBiomedicines, 2021
A series of dietary flavonoid acacetin 7-O-methyl ether derivatives were computationally designed aiming to improve the selectivity and potency profiles against monoamine oxidase (MAO) B.
Vedanjali Gogineni   +8 more
doaj   +1 more source

Activity of Novel Tryptophan Analogs against Mammalian and Trypanosomal Monoamine Oxidases [PDF]

open access: yes, 2005
Monoamine oxidases were assayed in live Trypanosoma brucei brucei and in trypanosomal homogenate using the oxygen electrode method. Serotonin and tryptamine were used as standard monomine oxidase A and B substrates, respectively.
Markham, A   +9 more
core   +1 more source

Cannabis‐Based Oil for Pain and Other Non‐Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial

open access: yesMovement Disorders, EarlyView.
Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota   +14 more
wiley   +1 more source

Monoamine oxidase in neuronal cell death [PDF]

open access: yes, 2008
Monoamine oxidase (MAO) is an oxidative enzyme that deaminates a variety of amine substrates, including the neurotransmitter dopamine. The enzymatic reaction requires molecular oxygen and produces hydrogen peroxide as a by-product.
Fitzgerald, J
core  

Apathy in Lewy Body Disorders: A Position Paper

open access: yesMovement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky   +12 more
wiley   +1 more source

Lysyl Oxidase-like Protein Recognizes Viral Envelope Proteins and Bacterial Polysaccharides against Pathogen Infection via Induction of Expression of Antimicrobial Peptides

open access: yesViruses, 2022
Lysyl oxidases (LOXs) are copper-dependent monoamine oxidases, and they play critical roles in extracellular matrix (ECM) remodeling. The LOX and LOX-like (LOXL) proteins also have a variety of biological functions, such as development and growth ...
Peng-Yuan Lu   +3 more
doaj   +1 more source

MONOAMINE OXIDASE A (MAOA), CHILDHOOD TRAUMA, ALCOHOLISM AND AGGRESSION [PDF]

open access: yes, 2008
Women who have experienced childhood sexual abuse (CSA) have an increased risk of alcoholism and antisocial personality disorder (ASPD). Among males, a functional polymorphism (MAOA-LPR, monoamine oxidase A linked polymorphic region) in the promoter ...
DUCCI, FRANCESCA
core  

Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records

open access: yesMovement Disorders, EarlyView.
Abstract Background Ursodeoxycholic acid (UDCA) has shown mitochondrial and neuroprotective effects and has been proposed as a treatment for Parkinson's disease (PD). However, population‐level evidence on its effect on PD risk is lacking. Objectives To compare the risk of incident PD among UDCA initiators versus matched non‐initiators within a ...
Chengsheng Ju   +7 more
wiley   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

open access: yesNeurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy